Ablynx Signs Exclusive License Agreement With Eddingpharm To Develop And Commercialise Its Anti-tnfa Nanobody In Greater China - Yahoo Finance

September 4, 2014

The Company is headquartered in Ghent, Belgium. More information can be found on www.ablynx.com . About Eddingpharm Founded in 2001, Eddingpharm is a fast growing specialty pharmaceutical company in http://www.migente.com/your_page/blog/view_posting.html?pid=5485944&profile_id=8198513&profile_name=andrestqri&user_id=8198513&username=andrestqri the Chinese market, committed to actively introducing quality products into China's pharmaceutical market. The Company focuses on the development and promotion of pharmaceutical products in four therapeutic areas: clinical nutrition, oncology, antibiotics and respiratory system. Eddingpharm has backlinks established long-term cooperative relationships with a number of multinational pharmaceutical companies and overseas specialty pharmaceutical companies, and has built up a competitive product portfolio and pipeline in the four major therapeutic areas. Eddingpharm recently established its US affiliate and set up a product development team with R&D capabilities in Los Angeles, CA, USA, to coordinate and communicate with leading global R&D institutions and explore opportunities for introducing innovative pharmaceutical products in China.
More: http://finance.yahoo.com/news/ablynx-signs-exclusive-license-agreement-050527500.html

Go Back

Comment